Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
EBITDA · Q4 FY2026 · quarter ended Sep 2026
EBITDA turns negative
Q4 FY2026 EBITDA was -$405.71M, compared with $64.2M a year earlier. Trailing-twelve-month EBITDA was -$603.58M.
Context
- EBITDA amounted to 133.9% of revenue in FY2026, up 114.0 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$663.07M (-9.9%) for the fiscal year ending Sep 2027, a step up from the -466.2% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$405.71M-174.7% QoQ
- Last fiscal yearSep 2026
- -$603.59M-466.2% YoY
- LTMSep 2026
- -$603.58M-466.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -731.9% | -147.1% | +584.9 pp |
| 1 year | -466.2% | -9.9% | +456.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2026
- (603.59M) USD
- Year-over-year change
- -466.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | (603.59M) | -466.2% |
| FY2025 | 2025-09-30 | 164.82M | +129.4% |
| FY2024 | 2024-09-30 | (561.51M) | -219.6% |
| FY2023 | 2023-09-30 | (175.67M) | -8.2% |
| FY2022 | 2022-09-30 | (162.29M) | — |
EBITDA vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -466.2% is the lowest of 6, against a peer median of -67.7%.
- EBITDA amounts to 133.9% of revenue for ARWR, versus a peer median of 196.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.15B USD | +773.6% | — | 24.0% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$174.59M USD | -68.4% | — | 243.2% | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Sep 2026 | -$603.58M USD | -466.2% | — | 133.9% | |
| Peer median (excluding ARWR) | — | -67.7% | — | 196.0% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 243.23M | 240.74M | 3.55M | 829.45M | 450.82M |
| Cost of Revenue | 10.42M | 12.49M | 18.6M | 0 | 1.8M |
| Gross Profit | 232.81M | 228.24M | (15.04M) | 829.45M | 449.02M |
| Gross Margin | 95.7% | 94.8% | -423.7% | 100.0% | 99.6% |
| Research & Development | 288.5M | 342.31M | 489.22M | 607.16M | 739.14M |
| Selling, General & Admin | 124.43M | 90.93M | 96.82M | 121.92M | 202.05M |
| Operating Expenses | 411.32M | 433.24M | 586.04M | 731.1M | 1.16B |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| EBITDA | (162.29M) | (175.67M) | (561.51M) | 164.82M | (603.59M) |
| EBITDA Margin | -66.7% | -73.0% | -15812.8% | 19.9% | -133.9% |
| Operating Income | (178.51M) | (205M) | (601.08M) | 98.35M | (707.17M) |
| Operating Margin | -73.4% | -85.2% | -16927.1% | 11.9% | -156.9% |
| Interest Income | 5.03M | 15.3M | 22.72M | 37.29M | 57.86M |
| Interest Expense | 0 | 18.33M | 32.35M | 89.36M | 93.71M |
| Other Income / Expenses | 5.8M | (1.49M) | (11.38M) | (46.81M) | (16.74M) |
| Income Before Tax | (172.71M) | (206.49M) | (612.46M) | 51.53M | (723.92M) |
| Pre-Tax Margin | -71.0% | -85.8% | -17247.5% | 6.2% | -160.6% |
| Income Tax Expense | 3.79M | 2.78M | (2.77M) | 21.42M | (6.78M) |
| Net Income | (176.06M) | (205.28M) | (599.49M) | (1.63M) | (724.21M) |
| Net Margin | -72.4% | -85.3% | -16882.4% | -0.2% | -160.6% |
| EPS (Basic) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| EPS (Diluted) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| Weighted Avg Shares | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
| Weighted Avg Shares (Diluted) | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.